Selected amongst global academic institutions to conduct a pivotal trial for heavy menstrual bleeding
OhmBody, a new "science-forward" division of Spark Biomedical, targets women's monthly period symptoms with $719 earpiece that uses nerve stimulation following Spark's $15M Series A funding round in April.
According to Hazelden Betty Ford, a neurostimulation device made by Spark Biomedical shows promise in helping adults and young adults emerge from addiction.
Final enrollment concludes for Spark Biomedical's pivotal study investigating a non-invasive, drug-free neurostimulation therapy aimed at improving treatment retention for adults with opioid use disorder.
The investment will support the company’s core areas of bioelectronic medicine, including neurological health, hemostasis, and women’s health.
Clinical enrollment concludes for Spark Biomedical’s pivotal trial investigating a non-invasive, drug-free neurostimulation treatment for newborns born with NOWS.
New Health Canada Approval Allows Spark Biomedical to Offer Drug-Free Opioid Withdrawal Relief Across Canada.
This trial will test the feasibility of wearable neurostimulation to help reduce fatal disorientation-related errors in the military.
2024 audits of ISO 13485 from DEKRA confirm Spark Biomedical meets international standards for quality management systems.
Spark Biomedical launches a unique fellowship program that enables neurosurgery residents to collaborate with medical device industry leaders advancing technology and shaping the future of healthcare.
